HR+ HER2- | Right Decisions

Please update your RDS mobile app to version 4.7.1

We are pleased to advise that deep linking capability, enabling users to directly download individual mobile toolkits, has now been released on the RDS mobile app. When you install the update, you will see that each toolkit has a small QR code icon the header area beside the search icon – see screenshot below. Clicking on this icon will open up a window with a full-size QR code and the alternative of a short URL for sharing with users. Instructions are provided.

You may need to actively install the update to install RDS app version 4.7.1 to see this improvement. Installing this update is also strongly recommended to get the full benefits of the new contingency arrangements – specifically, that if the RDS website should fail, you will still be able to download new mobile app toolkits.

To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number. To install latest updates:

On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.

On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.

Please get in touch with ann.wales3@nhs.scot with any questions.

Throughout the patient pathway, consideration should be given to patient eligibility and suitability for available clinical trials and discussed with individual patients as appropriate.

Author	Pete Hall and Judy Fraser (on behalf of SACT subgroup)	Reviewer	Frances Yuille
Date of creation/update	Created 20/09/2023 Updated 09/02/2024	Version number	1.1
Review date	20/09/2026	contact	nss.scottishcancernetwork@nhs.scot

The printing of visual pathways is strongly discouraged, due to the inability to print all relevant information contained within and behind the pathways. Any user choosing to do so must acknowledge that the information may be incomplete and that essential context may be missing from a printed or reproduced pathway.

SHTG Recommendation: The use of tumour profiling tests is recommended for patients who have an intermediate risk of distant recurrence, defined using a validated tool such as PREDICT or the NPI. Use is unlikely to provide additional benefit for decision making about adjuvant chemotherapy for patients with low or high clinical risk of distant recurrence.

HR+ HER2- Adjuvant

HR+ HER2- Neoadjuvant